Tirzepatide 15.0 mg: Dosing Guide & What to Expect

The 15.0 mg dose of Tirzepatide represents an important step in your treatment with this approved GLP-1 receptor agonist. Here is what clinical data and prescribing guidelines say about this specific dose.

What Is Tirzepatide 15.0 mg?

Tirzepatide (Mounjaro, Zepbound) is a GIP/GLP-1 dual receptor agonist administered by weekly subcutaneous injection. The 15.0 mg dose is the maintenance dose in the standard titration protocol, designed to progressively increase receptor engagement and clinical efficacy.

Clinical trial data from SURMOUNT-1 demonstrates a mean weight loss of approximately 22.5% at the maximum dose (15 mg) in trial-eligible participants. Results at intermediate doses like 15.0 mg are typically lower.

Titration Schedule for Tirzepatide

Tirzepatide 15.0 mg is the maximum approved dose. Most patients remain at this maintenance dose for the duration of treatment. Discuss long-term continuation with your prescriber.

Side Effects at 15.0 mg

The most commonly reported side effects of Tirzepatide include GI-related symptoms that tend to be most pronounced during dose escalation. At 15.0 mg (a higher titration step), some patients experience more pronounced GI symptoms than at lower doses.

• •Nausea
• •Diarrhea
• •Vomiting
• •Constipation
• •Abdominal Pain
• •Injection Site Reaction
• •Fatigue

Most side effects are transient and improve within 2–4 weeks at a stable dose. GI symptoms (nausea, diarrhea, constipation) are the most common reasons for dose reduction or discontinuation.

When to Call Your Doctor

• Persistent vomiting preventing adequate hydration
• Severe abdominal pain that does not resolve
• Signs of pancreatitis (severe upper abdominal pain radiating to back)
• Any signs of allergic reaction
• Heart rate increase of >20 bpm at rest that persists

When to Escalate from 15.0 mg

Standard protocol calls for 4 weeks at each dose level before escalation, provided the dose is well tolerated. If side effects are significant, your prescriber may recommend staying at 15.0 mg for an additional 4 weeks (an 8-week interval) before moving up.

Do not escalate doses without prescriber guidance. Self-directed dose escalation increases the risk of adverse events.

Contraindications & Safety

This medication is FDA-approved. Key contraindications include:

• Personal or family history of medullary thyroid carcinoma
• MEN type 2
• Hypersensitivity to tirzepatide

Pregnancy: Not recommended. Discuss with your prescriber if pregnancy is a possibility.